Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanzalintinib in Advanced Hepatocellular Carcinoma
NCT07042919Phase 2Recruiting
- Start
- Mar 2026
- Primary completion
- Mar 2029
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of zanzalintinib in hepatocellular carcinoma (HCC). Started Mar 2026; status: recruiting.
02
Drugs
zanzalintinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07042919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07042919.